Tricribine (TCN), an Akt inhibitor, significantly inhibited p-Akt, HIF-1α, and VEGF expression in vitro and in vivo, enhancing the radiosensitivity of ESCC in vitro and in vivo (89). The gene discussed is AKT1; the disease is esophageal squamous cell carcinoma.